 | Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. They're each showing a nice estimated 1yr ROI, increasing earnings, and pay at least a minimal dividend. I believe each of these has a greater potential return than analysts currently expect. As with all of my investments, I'll start with a small positions and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market. |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
(Summary) (Company) (Chart)
(Summary) (Company) (Chart)
| 30 July 2017 Price $6.96 1yr Target $7.67 Analysts 5 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 10.20% Yield 0.00% 1yr Tot Return 10.20% P/E --- PEG --- Beta 2.41 | EPS (ttm) $-1.63 EPS next yr $-1.49 Forward P/E --- EPS next 5yr --- 1yr Price Support --- Market Cap $648.25 Mil Revenues $57.40 Mil Earnings $-142.20 Mil Profit Margin --- Quick Ratio 3.40 Current Ratio 3.50 Debt/Equity --- | 1yr RevGR 117.24% 3yr RevGR 36.16% 5yr RevGR -2.47% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -65.10% ROE 108.30% |
 |
NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.
(Summary) (Company) (Chart)
| 30 July 2017 Price $20.07 1yr Target $23.00 Analysts 5 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 14.59% Yield 0.00% 1yr Tot Return 14.59% P/E --- PEG --- Beta --- | EPS (ttm) $-1.33 EPS next yr $-0.26 Forward P/E --- EPS next 5yr 60.00% 1yr Price Support --- Market Cap $1.77 Bil Revenues $104.70 Mil Earnings $-114.50 Mil Profit Margin --- Quick Ratio 6.80 Current Ratio 7.60 Debt/Equity 0.75 | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -42.10% ROE -74.30% |
 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
(Summary) (Company) (Chart)
| 30 July 2017 Price $30.13 1yr Target $44.20 Analysts 10 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 46.69% Yield 0.00% 1yr Tot Return 46.69% P/E --- PEG --- Beta 3.92 | EPS (ttm) $-2.61 EPS next yr $-2.05 Forward P/E --- EPS next 5yr 28.90% 1yr Price Support --- Market Cap $3.64 Bil Revenues $32.60 Mil Earnings $-309.50 Mil Profit Margin --- Quick Ratio 10.70 Current Ratio 10.80 Debt/Equity 0.00 | 1yr RevGR 28,411.47% 3yr RevGR 145.13% 5yr RevGR 153.00% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -58.40% ROE -63.10% |
 |
RSS Feed
